Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Psychedelics Have Returned to the Research Mainstream, Potential for a Groundbreaking Change in the Ways We Treat Mental Illness and Addiction

Psychiatrist Dr. Alex Dimitriu on Psychedelics in Psychiatry, Offers Tips on New Research.


News provided by

Dr. Alex Dimitriu

Nov 08, 2018, 11:00 ET

Share this article

Share toX

Share this article

Share toX

Dr. Alex Dimitriu
Dr. Alex Dimitriu

MENLO PARK, Calif., Nov. 8, 2018 /PRNewswire-PRWeb/ -- Most of us associate psychedelics with the 1960s, a time of great social and artistic change when hallucinogens like LSD, psilocybin, and others were promoted as a means of expanding consciousness. But before psychedelics were swept up by the counterculture, leading psychiatrists and researchers were studying – often with government funding – their use in treating alcoholism, obsessive-compulsive disorder, schizophrenia, end-of-life anxiety and more.

"Many of these studies reported positive results," says psychiatrist Dr. Alex Dimitriu, "but when psychedelics escaped the lab and their uncontrolled recreational use spread, the promise of these substances was supplanted by fear about their effects and concern about abuse and in 1970, their use was prohibited for any purpose. Research came to a halt and the knowledge of what psychedelics could do was all but lost." More recently, however, psychedelics have returned to the research mainstream and shown the potential for a groundbreaking change in the ways we treat mental illness and addiction.

More recently psychedelics have returned to the research mainstream and shown the potential for a groundbreaking change in the ways we treat mental illness and addiction.

Post this

Psychedelics are drugs that produce radical changes in consciousness, including hallucinations. Some work by binding to the same receptors in the brain as serotonin, a neurotransmitter associated with feelings of well-being; others increase the activity levels of serotonin and other neurotransmitters, such as dopamine, which produces euphoric effects.

Dr. Dimitriu says that research to date appears to show the greatest promise for psilocybin, the active ingredient in 'magic mushrooms' and MDMA, known as 'ecstasy.' "With proper safeguards and therapeutic guidance, these drugs have the potential to change the way we think – to uproot deeply ingrained habits of mind and lead to insights that might otherwise take years to achieve. If we can change the deeply rooted beliefs and thoughts that afflict people with conditions like depression, chronic anxiety, and PTSD, we can make deep and lasting improvements in quality of life."

Dr. Dimitriu highlighted some of the recent research into the uses of psychedelics in psychiatry:
Psilocybin has been studied in conjunction with psychotherapy to treat cancer patients who have developed depression, anxiety, and reduced quality of life that had been resistant to treatment by conventional drugs like antidepressants and benzodiazepines. In one study, a single dose of psilocybin given with psychological support to patients with a life-threatening cancer diagnosis produced substantial decreases in depression and death anxiety along with increases in quality of life, effects that lasted at least six months.

Psilocybin has also shown promising results in smoking cessation. In a preliminary study, 80 percent of smokers remained nicotine-free six months after three psilocybin sessions and 60 percent were nicotine-free for an average of 30 months after treatment.

The use of MDMA (or ecstasy) for treatment of post-traumatic stress disorder (PTSD) is in Phase III clinical trials and has been granted "breakthrough therapy" status by the FDA, making it the psychedelic treatment closest to approval. MDMA produces a euphoric state characterized by emotional openness, empathy, and decreased negative thoughts. Unlike recreational use, MDMA-assisted therapy for PTSD uses tightly controlled dosages accompanied by professional psychotherapy. Many of the patients who have undergone this therapy have been war veterans and many have had PTSD that had been particularly resistant to treatment. They reported that the MDMA-assisted therapy helped them approach reliving their trauma, which would normally produce overwhelming fear and anxiety, more safely and with greater acceptance and compassion.

Additional preliminary studies have examined the use of psychedelics for eating disorders, obsessive-compulsive disorder, depression, and social anxiety in people with autism. "What makes psychedelics so powerful?" Dr. Dimitriu asks. "Scientists and psychiatrists suggest that they work on an emotional as well as a biological level, that they make a person more open, more accepting, more appreciative of new experiences and imagination." Some believe that disorders that are characterized by rigid patterns of thinking, like chronic anxiety and obsessive-compulsive disorder, can be helped by a psychedelic experience that disrupts those patterns.

"It is vital that people understand that recreational, unsupervised use of psychedelics continues to be dangerous," Dr. Dimitriu emphasizes. "These are powerful drugs with many serious adverse side effects. They must be used only in controlled settings with professional therapeutic support. It should be understood that these medications are like being strapped to a very powerful rocket, so depending on guidance (in this case, the therapeutic setting) – things can go very well, or very badly, or possibly have no benefit at all. Only as the research progresses and we understand how psychedelics can be put to best use, will we be able to truly realize the benefits of 'changing our minds.'"

Alex Dimitriu, MD, is double board-certified in psychiatry and sleep medicine and is the founder of the Menlo Park Psychiatry and Sleep Medicine Center in Menlo Park, CA. http://www.doctoralex.com

SOURCE Dr. Alex Dimitriu

Related Links

http://www.doctoralex.com

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.